Media & Press Updates
News and updates about EnClear Therapies, as well as industry news and analysis. If you have any questions about our articles, please get in touch today.
April 22, 2020
EnClear Therapies, announced as Best Neurodegenerative Disease Therapy Specialists 2020 by Global Health & Pharma as part of the 2020 Biotechnology Awards.
February 18, 2020
EnClear Therapies, a life sciences company developing device-based therapies for the treatment of neurodegenerative disease, today announced a $10 million Series A financing led by 20/20 HealthCare Partners (“20/20 HCP”), and joined by Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities), Christian Angermayer’s Presight Capital and Dolby Ventures.
March 14, 2019
EnClear Therapies, a biotechnology company developing device-based therapies for the treatment of neurodegenerative disease, today announced that the company had secured approximately $2 million in seed funding and that it has hired Kevin Kalish as Vice President of Research and Development.
December 31, 2018
Medical device startups are becoming increasingly ambitious when it comes to treating diseases that are ill-served by drugs. The latest on this front is Enclear Therapies Inc., a Cambridge, Mass.-based company that is developing a device to clear toxic proteins from cerebrospinal fluid (CSF) to treat diseases such as amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP) and other neurological diseases.
December 27, 2018
EnClear to present at the Biotech Showcase 2019
EnClear Therapies will present at the Biotech Showcase 2019 conference, occurring January
7-9, 2019 at the Hilton San Francisco Union Square in San Francisco. Mr. DePasqua is scheduled to
present on Wednesday, January 9, 2019, 3:10 PM, Track: Franciscan C (Ballroom Level).